Market Research Logo

Multiple Sclerosis  - Market Insights, Epidemiology and Market Forecast – 2025

DelveInsight’s 'Multiple Sclerosis  - Market Insights, Epidemiology and Market Forecast – 2025” report provides an overview of the disease and in depth research related to Multiple Sclerosis  for the 7MM (United States, Germany, France, Italy, Spain and UK) for the study period undertaken from 2015-2025.

This report provides understanding of the patients affected, diagnosed patterns, treatment trends, unmet medical needs and current developments for Multiple Sclerosis  . It enables understanding of the historical and forecasted epidemiological data for the diagnosed prevalent cases of Multiple Sclerosis  for 7 major markets. The market outlook also provides understanding of country specific revenue and share by analyzing performance of the current therapies and thorough potential uptake of new products.
The market revenue of Multiple Sclerosis is currently accounted by several approved therapies, some of which are dimethyl fumarate (Tecfidera; Biogen), Natalizumab (Tysabri; Biogen), Glatiramer acetate (Copaxone; Teva Pharmaceutical), Gilenya (Novartis), Extavia (Novartis), Aubagio (Sanofi) and others.
Ocrevus (Roche), a first-in-class anti-CD20 antibody, was approved by U.S.FDA ad EMA in 2017 to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS). It is the first drug approved by the FDA for PPMS and is expected to become a blockbuster product in coming years.

There are many potential therapies under development for Multiple Sclerosis, few of them being Daclizumab (Biogen), Ofatumumab (Novartis Pharmaceuticals), Ponesimod (Actelion), Opicinumab (Biogen), Ozanimod (Celgene), and Ublituximab (TG Therapeutics, Inc.).

The entry of such potential pipeline candidates, and continued uptake of existing therapies shall act as major market drivers during our forecast period.

Additionally, the Report highlights the frontrunners, the drivers and barriers for the Multiple Sclerosis  market, as well as treatment algorithm, current treatments & advancements are included.
The chapters including marketed products highlights the advantages and disadvantages associated with therapies associated with Multiple Sclerosis  , providing an in-depth analysis of emerging therapies which will create an impact through their launch.

According to DelveInsight, the forecasted patient population of Multiple Sclerosis  for the year 2025 will be XX, increasing at a CAGR of XX% from 2015 to 2025 and the Multiple Sclerosis  7MM market size is estimated to be USD XX by 2025. The DelveInsight Report will help in enhanced understanding of the Multiple Sclerosis  market from inside out, with transparency into the calculated patient forecasting data and estimated market size.

Key Coverage

• Understanding historical and forecasted epidemiological data for Multiple Sclerosis  covering 7MM from 2015-2025.
• Segment level epidemiology and market split for Multiple Sclerosis  .
• The thorough assessment of competitors, market, current trends & treatments along with upcoming treatments for Multiple Sclerosis  .
• The Report also covers the market size for 7MM (United States, EU 5 (Germany, Spain, Italy, France and United Kingdom) and Japan) from 2015-2025 and detailed historical and forecasted Multiple Sclerosis  market trends.
• Thorough market distribution based on market share for Multiple Sclerosis  .

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Multiple Sclerosis  market.
• To understand the future market competition in the Multiple Sclerosis  market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis  in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
• Identification of strong upcoming players in market will help in devising strategies that will help in getting ahead of competitors.


1. Report Introduction
2. Multiple Sclerosis Market Overview at a Glance
2.1. Global Market Size of Multiple Sclerosis in 2016
2.2. Global Market Size of Multiple Sclerosis in 2025
3. Disease Background and Overview: Multiple Sclerosis
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Multiple Sclerosis Geography wise Prevalent Cases
4.2.1. 7MM Prevalent Cases of Multiple Sclerosis in 2016
4.2.2. 7MM Prevalent Cases of Multiple Sclerosis in 2025
4.3. United States
4.3.1. Prevalent Cases of Multiple Sclerosis in United States (2015-2025)
4.3.2. Age-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.3.3. Sex-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.3.4. Sub-type Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
4.3.5. EDSS-based prevalence of Multiple Sclerosis in United States (2016)
4.4. EU-5
4.4.1. Assumptions and Rationale
4.4.2. Germany
4.4.2.1. Prevalent Cases of Multiple Sclerosis in Germany (2015-2025)
4.4.2.2. Age-Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.2.3. Sex-Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.2.4. Sub-type Specific Prevalence of Multiple Sclerosis in Germany (2015-2025)
4.4.2.5. EDSS-based prevalence of Multiple Sclerosis in Germany (2016)
4.4.3. Italy
4.4.3.1. Prevalent Cases of Multiple Sclerosis in Italy (2015-2025)
4.4.3.2. Age-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.3.3. Sex-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.3.4. Sub-type Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
4.4.3.5. EDSS-based prevalence of Multiple Sclerosis in Italy (2016)
4.4.4. Spain
4.4.4.1. Prevalent Cases of Multiple Sclerosis in Spain (2015-2025)
4.4.4.2. Age-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.4.3. Sex-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.4.4. Sub-type Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
4.4.4.5. EDSS-based prevalence of Multiple Sclerosis in Spain (2016)
4.4.5. France
4.4.5.1. Prevalent Cases of Multiple Sclerosis in France (2015-2025)
4.4.5.2. Age-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.5.3. Sex-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.5.4. Sub-type Specific Prevalence of Multiple Sclerosis in France (2015-2025)
4.4.5.5. EDSS-based prevalence of Multiple Sclerosis in France (2016)
4.4.6. United Kingdom
4.4.6.1. Prevalent Cases of Multiple Sclerosis in UK (2015-2025)
4.4.6.2. Age-Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.4.6.3. Sex-Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.4.6.4. Sub-type Specific Prevalence of Multiple Sclerosis in UK (2015-2025)
4.4.6.5. EDSS-based prevalence of Multiple Sclerosis in UK (2016)
4.5. Japan
4.5.1. Prevalent Cases of Multiple Sclerosis in Japan (2015-2025)
4.5.2. Age-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
4.5.3. Sex-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
4.5.4. Sub-type Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
4.5.5. EDSS-based prevalence of Multiple Sclerosis in Japan (2016)
5. Treatment Algorithm
5.1. United States
5.2. Europe
5.3. Japan
6. Marketed Products
6.1. Tecfidera: Biogen
6.1.1. Mechanism of action
6.1.2. Regulatory Milestones
6.1.3. Advantages and disadvantages
6.1.4. Safety and efficacy
6.1.5. Side effects
6.1.6. Product profile
6.2. Tysabri: Biogen
6.2.1. Mechanism of action
6.2.2. Regulatory Milestones
6.2.3. Advantages and disadvantages
6.2.4. Safety and efficacy
6.2.5. Side effects
6.2.6. Product profile
6.3. Copaxone: Teva Pharmaceutical
6.3.1. Mechanism of action
6.3.2. Regulatory Milestones
6.3.3. Advantages and disadvantages
6.3.4. Safety and efficacy
6.3.5. Side effects
6.3.6. Product profile
To be continued in report…
7. Key Emerging Therapies
7.1. Key Cross Competition
7.2. Ponesimod: Actelion Pharmaceuticals
7.2.1. Regulatory Milestones
7.2.2. Clinical Development
7.2.3. Product Profile
7.2.4. Clinical Pipeline Activity
7.2.4.1. Ongoing Trials Information
7.2.4.2. Clinical Trial by Phase
7.3. Ofatumumab: Novartis Pharmaceuticals
7.3.1. Regulatory Milestones
7.3.2. Clinical Development
7.3.3. Product Profile
7.3.4. Clinical Pipeline Activity
7.3.4.1. Ongoing Trials Information
7.3.4.2. Clinical Trial by Phase
To be continued in report…
8. Multiple Sclerosis Market Size
8.1. Key Findings
8.2. Market Size: Assumptions and Forecast Parameters
8.3. Total 7MM Multiple Sclerosis Market Analysis
8.3.1. Overview of Total Multiple Sclerosis Market (2015-2025)
9. 7MM Multiple Sclerosis : Country-Wise Market Analysis
9.1. United States Market Size
9.1.1. Market Analysis
9.1.2. Emerging therapies analysis: Impact on the market
9.2. Germany Market Size
9.2.1. Market Analysis
9.2.2. Emerging therapies analysis: Impact on the market
9.3. France Market Size
9.3.1. Market Analysis
9.3.2. Emerging therapies analysis: Impact on the market
9.4. United Kingdom Market Size
9.4.1. Market Analysis
9.4.2. Emerging therapies analysis: Impact on the market
9.5. Spain Market Size
9.5.1. Market Analysis
9.5.2. Emerging therapies analysis: Impact on the market
9.6. Italy Market Size
9.6.1. Market Analysis
9.6.2. Emerging therapies analysis: Impact on the market
9.7. Japan Market Size
9.7.1. Market Analysis
9.7.2. Emerging therapies analysis: Impact on the market
10. Report Methodology
10.1. Sources Used
11. Consulting Services
12. Disclaimer
13. About DelveInsight
Table 1 : Prevalent Cases of Multiple Sclerosis in United States (2015-2025)
Table 2 : Age-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Table 3 : Sex-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Table 4 : Sub-type Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Table 5 : EDSS-based prevalence of Multiple Sclerosis in United States (2016)
Table 6 : Prevalent Cases of Multiple Sclerosis in Germany (2015-2025)
Table 7 : Age-Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Table 8 : Sex-Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Table 9 : Sub-type Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Table 10 : EDSS-based prevalence of Multiple Sclerosis in Germany (2016)
Table 11 : Prevalent Cases of Multiple Sclerosis in France (2015-2025)
Table 12 : Age-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Table 13 : Sex-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Table 14 : Sub-type Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Table 15 : EDSS-based prevalence of Multiple Sclerosis in France (2016)
Table 16 : Prevalent Cases of Multiple Sclerosis in Italy (2015-2025)
Table 17 : Age-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Table 18 : Sex-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Table 19 : Sub-type Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Table 20 : EDSS-based prevalence of Multiple Sclerosis in Italy (2016)
Table 21 : Prevalent Cases of Multiple Sclerosis in Spain (2015-2025)
Table 22 : Age-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Table 23 : Sex-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Table 24 : Sub-type Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Table 25 : EDSS-based prevalence of Multiple Sclerosis in Spain (2016)
Table 26 : Prevalent Cases of Multiple Sclerosis in United Kingdom (2015-2025)
Table 27 : Age-Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Table 28 : Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Table 29 : Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Table 30 : EDSS-based prevalence of Multiple Sclerosis in United Kingdom (2016)
Table 31 : Prevalent Cases of Multiple Sclerosis in Japan (2015-2025)
Table 32 : Age-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Table 33 : Sex-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Table 34 : Sub-type Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Table 35 : EDSS-based prevalence of Multiple Sclerosis in Japan (2016)
Table 36 : Ponesimod, Clinical Trials by Recruitment status, 2017
Table 37 : Ponesimod, Clinical Trials by Zone, 2017
Table 38 : Ofatumumab, Clinical Trials by Recruitment status, 2017
Table 39 : Ofatumumab, Clinical Trials by Zone, 2017
Table 40 : Total 7 Major Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 41 : Region wise Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 42 : United States Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 43 : Germany Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 44 : France Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 45 : United Kingdom Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 46 : Spain Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 47 : Italy Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Table 48 : Japan Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 1 : Prevalent Cases of Multiple Sclerosis in United States (2015-2025)
Figure 2 : Age-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Figure 3 : Sex-Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Figure 4 : Sub-type Specific Prevalence of Multiple Sclerosis in United States (2015-2025)
Figure 5 : EDSS-based prevalence of Multiple Sclerosis in United States (2016)
Figure 6 : Prevalent Cases of Multiple Sclerosis in Germany (2015-2025)
Figure 7 : Age-Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Figure 8 : Sex-Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Figure 9 : Sub-type Specific Prevalence of Multiple Sclerosis in Germany(2015-2025)
Figure 10 : EDSS-based prevalence of Multiple Sclerosis in Germany (2016)
Figure 11 : Prevalent Cases of Multiple Sclerosis in France (2015-2025)
Figure 12 : Age-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Figure 13 : Sex-Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Figure 14 : Sub-type Specific Prevalence of Multiple Sclerosis in France (2015-2025)
Figure 15 : EDSS-based prevalence of Multiple Sclerosis in France (2016)
Figure 16 : Prevalent Cases of Multiple Sclerosis in Italy (2015-2025)
Figure 17 : Age-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Figure 18 : Sex-Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Figure 19 : Sub-type Specific Prevalence of Multiple Sclerosis in Italy (2015-2025)
Figure 20 : EDSS-based prevalence of Multiple Sclerosis in Italy (2016)
Figure 21 : Prevalent Cases of Multiple Sclerosis in Spain (2015-2025)
Figure 22 : Age-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Figure 23 : Sex-Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Figure 24 : Sub-type Specific Prevalence of Multiple Sclerosis in Spain (2015-2025)
Figure 25 : EDSS-based prevalence of Multiple Sclerosis in Spain (2016)
Figure 26 : Prevalent Cases of Multiple Sclerosis in United Kingdom (2015-2025)
Figure 27 : Age-Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Figure 28 : Sex-Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Figure 29 : Sub-type Specific Prevalence of Multiple Sclerosis in United Kingdom (2015-2025)
Figure 30 : EDSS-based prevalence of Multiple Sclerosis in United Kingdom (2016)
Figure 31 : Prevalent Cases of Multiple Sclerosis in Japan (2015-2025)
Figure 32 : Age-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Figure 33 : Sex-Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Figure 34 : Sub-type Specific Prevalence of Multiple Sclerosis in Japan (2015-2025)
Figure 35 : EDSS-based prevalence of Multiple Sclerosis in Japan (2016)
Figure 36 : Ponesimod, Clinical Trials by Recruitment status, 2017
Figure 37 : Ponesimod, Clinical Trials by Zone, 2017
Figure 38 : Ofatumumab, Clinical Trials by Recruitment status, 2017
Figure 39 : Ofatumumab, Clinical Trials by Zone, 2017
Figure 40 : Total 7 Major Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 41 : Region wise Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 42 : United States Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 43 : Germany Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 44 : France Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 45 : United Kingdom Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 46 : Spain Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 47 : Italy Market Size of Multiple Sclerosis in USD, Million (2015-2025)
Figure 48 : Japan Market Size of Multiple Sclerosis in USD, Million (2015-2025)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report